|
|
|
|
|
Documento senza titolo
PONTIFICIA ACADEMIA PRO VITA
Declaration on
THE PRODUCTION AND THE SCIENTIFIC AND THERAPEUTIC USE OF HUMAN EMBRYONIC STEM
CELLS
August 25th, 2000
|
Preface
Preface
This document seeks
to contribute to the debate on the production and use of embryonic stem cells
which is now taking place in the scientific and ethical literature and in public
opinion. Given the growing relevance of the debate on the limits and licitness
of the production and use of such cells, there is a pressing need to reflect on
the ethical implications which are present.
The first section
will very briefly set out the most recent scientific data on stem cells and the
biotechnological data on their production and use. The second section will draw
attention to the more relevant ethical problems raised by these new discoveries
and their applications.
Scientific aspects
Although some aspects
need to be studied more thoroughly, a commonly accepted definition of ?stem cell?
describes it as a cell with two characteristics: 1) the property of unlimited
self-renewal?that is, the ability to reproduce itself over a long period of time
without becoming differentiated; and 2) the capability to produce non-permanent
progenitor cells, with limited capacity for proliferation, from which derive
a variety of lineages of highly differentiated cells (neural cells, muscle cells,
blood cells, etc.). For about thirty years stem cells have provided a wide field
of research in adult tissues,[i] in embryonic tissues and in in vitro cultures
of embryonic stem cells of experimental animals.[ii] But public attention in
these cells has recently been drawn by the achievement of a new milestone: the
production of human embryonic stem cells.
Human embryonic stem cells
Today, the
preparation of human embryonic stem cells (human ES cells) implies the following:[iii]
1) the production of human embryos andor the use of the surplus embryos
resulting from in vitro fertilization or of frozen embryos; 2) the development
of these embryos to the stage of initial blastocysts; 3) the isolation of the
embryoblast or inner cell mass (ICM)?which implies the destruction of the embryo;
4) culturing these cells on a feeder layer of irradiated mouse fibroblasts in a
suitable medium, where they can multiply and coalesce to form colonies; 5)
repeated subculturing of these colonies, which lead to the formation of
cell
lines capable of multiplying indefinitely while preserving the characteristics
of ES cells for months and years.
These ES cells,
however, are only the point of departure for the preparation of differentiated
cell lines, that is, of cells with the characteristics proper of the various
tissues (muscle, neural, epithelial, haematic, germinal, etc.). Methods for
obtaining them are still being studied;[iv] but the injection of human ES cells
into experimental animals (mice) or their culture in vitro in controlled
environments to their confluence have shown that they are able to produce
differentiated cells which, in a normal development, would derive from the three
different embryonic tissue layers: endoderm (intestinal epithelium), mesoderm (cartilage,
bone, smooth and striated muscle) and ectoderm (neural epithelium, squamous
epithelium).[v]
The results of these
experiments have had a great impact on the world of both science and
biotechnology?especially medicine and pharmacology?no less than the world of
business and the mass media. There were high hopes that the application of this
knowledge would lead to new and safer ways of treating serious diseases,
something which had been sought for years.[vi] But the impact was greatest in
the political world.[vii] In the United States in particular, in response to the
long-standing opposition of Congress to the use of federal funds for research in
which human embryos were destroyed, strong pressure came from the National
Institutes of Health (NIH), among others, to obtain funds for at least using
stem cells produced by private groups; recommendations were also made by the
National Bioethics Advisory Committee (NBAC), established by the Federal
Government to study the problem, urging that public money should be given not
only for research on embryonic stem cells but also for producing them. Indeed,
persistent efforts are being made to rescind definitively the present legal ban
on the use of federal funds for research on human embryos.
Similar pressures are being brought
to bear also in England, Japan and Australia.
Therapeutic cloning
It had become clear
that the therapeutic use of ES cells, as such, entailed significant risks, since?as
had been observed in experiments on mice?tumours resulted. It would have been
necessary therefore to prepare specialized lines of differentiated cells as and
when they were needed; and it did not appear that this could be done in a short
period of time. But, even if successful, it would have been very difficult to be
certain that the inoculation or therapeutic implant was free of stem cells,
which would entail the corresponding risk. Moreover there would have been a need
for further treatment to overcome immunological incompatibility. For these
reasons, three methods of ?therapeutic cloning?[viii] were proposed, suitable
for preparing pluripotent human embryonic stem cells with well defined genetic
information from which the desired differentiation would then follow.
1. The replacement of
the nucleus of an oocyte with the nucleus of an adult cell of a given subject,
followed by embryonic development to the stage of blastocyst and the use of the
inner cell mass (ICM) in order to obtain ES cells and, from these, the desired
differentiated cells.
2. The transfer of a nucleus of a cell of a given subject into an oocyte of another animal. An
eventual success in this procedure should lead ?it is presumed?to the
development of a human embryo, to be used as in the preceding case.
3. The reprogramming of the nucleus
of a cell of a given subject by fusing the ES cytoplast with a somatic cell
karyoplast, thus obtaining a ?cybrid?. This is a possibility which is still
under study. In any event, this method too would seem to demand a prior
preparation of ES cells from human embryos.
Current scientific research is
looking to the first of these possibilities as the preferred method, but it is
obvious that?from a moral point of view, as we shall see?all three proposed
solutions are unacceptable.
Adult stem cells
From studies on adult
stem cells (ASC) in the last thirty years it had been clearly shown that many
adult tissues contain stem cells, but stem cells capable of producing only cells
proper to a given tissue. That is, it was not thought that these cells could be
reprogrammed. In more recent years,[ix] however, pluripotent stem cells were
also discovered in various human tissues?in bone marrow (HSCs), in the brain (NSCs),
in the mesenchyme (MSCs) of various organs, and in umbilical cord blood (PCB,
placentalcord blood); these are cells capable of producing different types of
cells, mostly blood cells, muscle cells and neural cells. It was learnt how to
recognize them, select them, maintain them in development, and induce them to
form different types of mature cells by means of growth factors and other
regulating proteins. Indeed noteworthy progress has already been made in the
experimental field, applying the most advanced methods of genetic engineering
and molecular biology in analyzing the genetic programme at work in stem cells,[x]
and in importing the desired genes into stem cells or progenitor cells which,
when implanted, are able to restore specific functions to damaged tissue.[xi] It
is sufficient to mention, on the basis of the reported references, that in human
beings the stem cells of bone marrow, from which the different lines of blood
cells are formed, have as their marker the molecule CD34; and that, when
purified, these cells are able to restore entirely the normal blood count in
patients who receive ablative doses of radiation and chemotherapy, and this with
a speed which is in proportion to the quantity of cells used. Furthermore, there
are already indications on how to guide the development of neural stem cells (NSCs)
through the use of various proteins?among them neuroregulin and bone
morphogenetic protein 2 (BMP2)?which can direct NSCs to become neurons or glia (myelin-producing
neural support cells) or even smooth muscle tissue.
The note of
satisfaction, albeit cautious, with which many of the cited works conclude is an
indication of the great promise that ?adult stem cells? offer for effective
treatment of many pathologies. Thus the affirmation made by D. J. Watt and G. E.
Jones: ?The muscle stem cell, whether it be of the embryonic myoblast lineage,
or of the adult satellite status, may well turn out to be a cell with far
greater importance to tissues other than its tissue of origin and may well hold
the key to future therapies for diseases other than those of a myogenic nature?
(p. 93). As J. A. Nolta and D. B. Kohn emphasize: ?Progress in the use of gene
transfer into haematopoietic cells has led to initial clinical trials.
Information developed by these early efforts will be used to guide future
developments. Ultimately, gene therapy may allow a number of genetic and
acquired diseases to be treated, without the current complications from bone
marrow transplantation with allogeneic cells.? (p. 460); and the confirmation
offered by D. L. Clarke and J. Frisén: ?These studies suggest that stem cells in
different adult tissues may be more similar than previously thought and perhaps
in some cases have a developmental repertoire close to that of ES cells? (p.
1663) and ?demonstrates that an adult neural stem cell has a very broad
developmental capacity and may potentially be used to generate a variety of cell
types for transplantation in different diseases? (p. 1660).
The progress and
results already obtained in the field of adult stem cells (ASC) show not only
their great plasticity but also their many possible uses, in all likelihood no
different from those of embryonic stem cells, since plasticity depends in large
part upon genetic information, which can be reprogrammed.
Obviously, it is not
yet possible to compare the therapeutic results obtained and obtainable using
embryonic stem cells and adult stem cells. For the latter, various
pharmaceutical firms are already conducting clinical experiments[xii] which are
showing some success and raising genuine hopes for the not too distant future.
As regards embryonic stem cells, even if various experimental approaches prove
positive,[xiii] their application in the clinical field?owing precisely to the
serious ethical and legal problems which arise?needs to be seriously
reconsidered and requires a great sense of responsibility towards the dignity of
every human being.
Ethical problems
Given the nature of
this document, the key ethical problems implied by these new technologies are
briefly presented below, with an indication of the responses which emerge from a
careful consideration of the human subject from the moment of conception. It is
this consideration which underlies the position affirmed and put forth by the
Magisterium of the Church.
The first ethical
problem, which is fundamental, can be formulated thus: Is it morally licit to
produce andor use living human embryos for the preparation of ES cells?
The answer is
negative, for the following reasons:
1. On the basis of a
complete biological analysis, the living human embryo is?from the moment of the
union of the gametes?a human subject with a well defined identity, which from
that point begins its own coordinated, continuous and gradual development, such
that at no later stage can it be considered as a simple mass of cells.[xiv]
2. From this it
follows that as a ?human individual? it has the right to its own life; and
therefore every intervention which is not in favour of the embryo is an act
which violates that right. Moral theology has always taught that in the case of
?ius certum tertii? the system of probabilism does not apply.[xv]
3. Therefore, the
ablation of the inner cell mass (ICM) of the blastocyst, which critically and
irremediably damages the human embryo, curtailing its development, is a gravely
immoral act and consequently is gravely illicit.
4. No end believed to
be good, such as the use of stem cells for the preparation of other
differentiated cells to be used in what look to be promising therapeutic
procedures, can justify an intervention of this kind. A good end does not make
right an action which in itself is wrong.
5. For Catholics,
this position is explicitly confirmed by the Magisterium of the Church which, in
the Encyclical Evangelium Vitae, with reference to the Instruction
Donum Vitae
of the Congregation for the Doctrine of the Faith, affirms: ?The Church has
always taught and continues to teach that the result of human procreation, from
the first moment of its existence, must be guaranteed that unconditional respect
which is morally due to the human being in his or her totality and unity as body
and spirit: "The human being is to be respected and treated as a person from the
moment of conception; and therefore from that same moment his rights as a person
must be recognized, among which in the first place is the inviolable right of
every innocent human being to life' (Donum vitae, I, 1)?.[xvi]
The second ethical
problem can be formulated thus: Is it morally licit to engage in so-called
?therapeutic cloning? by producing cloned human embryos and then destroying them
in order to produce ES cells?
The answer is
negative, for the following reason:
Every type of
therapeutic cloning, which implies producing human embryos and then destroying
them in order to obtain stem cells, is illicit; for there is present the ethical
problem examined above, which can only be answered in the negative.[xvii]
The third ethical
problem can be formulated thus: Is it morally licit to use ES cells, and the
differentiated cells obtained from them, which are supplied by other researchers
or are commercially obtainable?
The answer is negative, since:
Prescinding from the
participation?formal or otherwise?in the morally illicit intention of the
principal agent, the case in question entails a proximate material cooperation
in the production and manipulation of human embryos on the part of those
producing or supplying them.
Conclusions
It is not hard,
therefore, to see the seriousness and gravity of the ethical problem posed by
the desire to extend to the field of human research the production andor use of
human embryos, even for an humanitarian perspective.
The possibility, now
confirmed, of using adult stem cells to attain the same goals as would be sought
with embryonic stem cells?even if many further steps in both areas are necessary
before clear and conclusive results are obtained?indicates that adult stem cells
represent a more reasonable and human method for making correct and sound
progress in this new field of research and in the therapeutic applications which
it promises. These applications are undoubtedly a source of great hope for a
significant number of suffering people.
Pontificia Academia
pro Vita, Vatican City, August 25, 2000.
Juan de Dios Vial Correa,
President
+ Mons. Elio Sgreccia,
Vice- President
(Translated into English from the
original Italian text published in ?L'Osservatore Romano? Friday, 25 August
2000, p. 6.)
|
|
NOTES
NOTES
--------------------------------------------------------------------------------
[i] Cf. M. Loeffler,
C. S. Potten, Stem Cells and Cellular Pedigrees: a Conceptual Introduction, in:
C. S. Potten (ed.), Stem Cells, Academic Press, London 1997, 1-27; D. Van der
Kooy, S. Weiss, Why Stem Cells?, Science 2000, 287, 1439-1441.
[ii] Cf. T. Nakano,
H. Kodama, T. Honjo, Generation of Lymphohematopoietic Cells from Embryonic Stem
Cells in Culture, Science 1994, 265, 1098-1101; G. Keller, In Vitro Differentiation of Embryonic Stem Cells, Current Opinion in Cell Biology 1995,
7, 862-869; S. Robertson, M. Kennedy, G. Keller, Hematopoietic Commitment During
Embryogenesis, Annals of the New York Academy of Sciences 1999, 872, 9-16.
[iii] Cf. J. A.
Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., Embryonic Stem Cell Lines
Derived from Human Blastocysts, Science 1998, 282, 1145-1147; G. Vogel,
Harnessing the Power of Stem Cells, Science 1999, 283, 1432-1434.
[iv] Cf. F. M. Watt,
B. L. M. Hogan, Out of Eden: Stem Cells and Their Niches, Science 2000, 287,
1427-1430.
[v] Cf. J. A. Thomson,
J. Itskovitz-Eldor, S. S. Shapiro et al., op. cit.
[vi] Cf. U.S.
Congress, Office of Technology Assessment, Neural Grafting: Repairing the Brain
and Spinal Cord, OTABA-462, Washington, DC, U.S. Government Printing Office,
1990; A. McLaren, Stem Cells: Golden Opportunities with Ethical Baggage, Science
2000, 288, 1778.
[vii] Cf. E. Marshall,
A Versatile Cell Line Raises Scientific Hopes, Legal Questions, Science 1998,
282, 1014-1015; J. Gearhart, New Potential for Human Embryonic Stem Cells, ibid.,
1061-1062; E. Marshall, Britain Urged to Expand Embryo Studies, ibid., 21672168;
73 Scientists, Science Over Politics, Science 1999, 283, 1849-1850; E. Marshall,
Ethicists Back Stem Cell Research, White House Treads Cautiously, Science 1999,
285, 502; H. T. Shapiro, Ethical Dilemmas and Stem Cell Research, ibid., 2065;
G. Vogel, NIH Sets Rules for Funding Embryonic Stem Cell Research, Science 1999,
286, 2050; G. Keller, H. R. Snodgrass, Human Embryonic Stem Cells: the Future Is
Now, Nature Medicine 1999, 5, 151-152; G. J. Annas, A. Caplan, S. Elias, Stem
Cell Politics, Ethics and Medical Progress, ibid., 1339-1341; G. Vogel, Company Gets Rights to Cloned Human Embryos, Science 2000, 287, 559; D. Normile,
Report
Would Open Up Research in Japan, ibid., 949; M. S. Frankel, In Search of Stem
Cell Policy, ibid., 1397; D. Perry, Patients Voices: the Powerful Sound in the
Stem Cell Debate, ibid., 1423; N. Lenoir, Europe Confronts the Embryonic Stem
Cell Research Challenge, ibid., 1425-1427; F. E. Young, A Time for Restraint,
ibid., 1424; Editorial, Stem Cells, Nature Medicine 2000, 6, 231.
[viii] D. Solter, J.
Gearhart, Putting Stem Cells to Work, Science 1999, 283, 1468-1470.
[ix] Cf. C. S. Potten
(ed.), Stem Cells, Academic Press, London 1997, 474; D. Orlic, T. A. Bock, L.
Kanz, Hemopoietic Stem Cells: Biology and Transplantation, Ann. N. Y. Acad.
Sciences, vol. 872, New York 1999, 405; M. F. Pittenger, A. M. Mackay, S. C.
Beck et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells,
Science 1999, 284, 143-147; C. R. R. Bjornson, R. L. Rietze, B. A. Reynolds et
al., Turning Brain into Blood: a Hematopoietic Fate Adopted by Adult Neural Stem
Cells in Vivo, Science 1999, 283, 534-536; V. Ourednik, J. Ourednik, K. I. Park,
E. Y. Snyder, Neural Stem Cells: a Versatile Tool for Cell Replacement and Gene
Therapy in the Central Nervous System, Clinical Genetics 1999, 56, 267-278; I.
Lemischka, Searching for Stem Cell Regulatory Molecules: Some General Thoughts
and Possible Approaches, Ann. N. Y. Acad. Sci. 1999, 872, 274-288; H. H. Gage,
Mammalian Neural Stem Cells, Science 2000, 287, 1433-1438; D. L. Clarke, C. B.
Johansson, J. Frisén et al., Generalized Potential of Adult Neural Stem Cells,
Science 2000, 288, 1660-1663; G. Vogel, Brain Cells Reveal Surprising
Versatility, ibid., 1559-1561.
[x] Cf. R. L.
Phillips, R. E. Ernst, I. R. Lemischka et al., The Genetic Program of
Hematopoietic Stem Cells, Science 2000, 288, 1635-1640.
[xi] Cf. D. J. Watt,
G. E. Jones, Skeletal Muscle Stem Cells: Function and Potential Role in Therapy,
in: C. S. Potten, Stem Cells, op. cit., 75-98; J. A. Nolta, D. B. Kohn,
Haematopoietic Stem Cells for Gene Therapy, ibid., 447-460; Y. Reisner, E.
Bachar-Lustig, H-W. Li et al., The Role of Megadose CD34+ Progenitor Cells in
the Treatment of Leukemia Patients Without a Matched Donor and in Tolerance
Induction for Organ Transplantation, Ann. N.Y. Acad. Sci. 1999, 872, 336-350; D.
W. Emery, G. Stamatoyannopoulos, Stem Cell Gene Therapy for the ß-Chain Hemoglobinopathies, ibid., 94-108; M. Griffith, R. Osborne, R. Munger,
Functional Human Corneal Equivalents Constructed from Cell Lines, Science 1999,
286, 2169-2172; N. S. Roy, S. Wang, L. Jiang et al., In Vitro Neurogenesis by
Progenitor Cells Isolated from the Adult Hippocampus, Nature Medicine 2000, 6,
271-277; M. Noble, Can Neural Stem Cells Be Used as Therapeutic Vehicles in the
Treatment of Brain Tumors?, ibid., 369-370; I. L. Weissman, Translating Stem and
Progenitor Cell Biology to the Clinic: Barriers and Opportunities, Science 2000,
287, 1442-1446; P. Serup, Panning for Pancreatic Stem Cells, Nature Genetics
2000, 25, 134-135.
[xii] E. Marshall,
The Business of Stem Cells, Science 2000, 287, 1419-1421.
[xiii] Cf. O. Brustle,
K. N. Jones, R. D. Learish et al., Embryonic Stem Cell-Derived Glial Precursors:
a Source of Myelinating Transplants, Science 1999, 285, 754-756; J. W. McDonald,
X-Z Liu, Y. Qu et al., Transplanted Embryonic Stem Cells Survive, Differentiate
and Promote Recovery in Injured Rat Spinal Cord, Nature Medicine 1999, 5,
1410-1412.
[xiv] Cf. A. Serra,
R. Colombo, Identity and Status of the Human Embryo: the Contribution of Biology,
in: Pontificia Academia pro Vita, Identity and Statute of Human Embryo, Libreria
Editrice Vaticana, Città del Vaticano 1998, 128-177.
[xv] Cf. I. Carrasco
De Paula, The Respect Due to the Human Embryo: a Historical and Doctrinal
Perspective, in: Pontificia Academia pro Vita, op. cit., 48-73; R. Lucas Lucas,
The Anthropological Status of the Human Embryo, in: ibid., 178-205; M. Cozzoli,
The Human Embryo: Ethical and Normative Aspects, in: ibid., 260-300; L. Eusebi,
Protection of the Human Embryo: Juridical Profiles, in: ibid., 301-313.
[xvi] John Paul II,
Encyclical Letter Evangelium vitae (25 March 1995), no. 60, in: Acta Apostolicae
Sedis 87 (1995) 469. Cf. also Congregation for the Doctrine of the Faith,
Instruction on Respect for Human Life in its Origin and on the Dignity of
Procreation Donum vitae (22 February 1987), in: Acta Apostolicae Sedis 80 (1988)
70-102.
[xvii] Congregation
for the Doctrine of the Faith, op. cit., I, no. 6, in: Acta Apostolicae Sedis 80
(1988) 84-85; C. B. Cohen (ed.), Special Issue: Ethics and the Cloning of Human
Embryos, Kennedy Institute of Ethics Journal 1994, no. 4, 187-282; H. T. Shapiro,
Ethical and Policy Issues of Human Cloning, Science 1997, 277, 195-196; M. L. Di
Pietro, Dalla clonazione animale alla clonazione dell'uomo?, Medicina e Morale
1997, no. 6, 1099-2005; A. Serra, Verso la clonazione dell'uomo? Una nuova
frontiera della scienza, La Civiltà Cattolica 1998 I, 224-234; Id., La
clonazione umana in prospettiva « sapienziale », ibid., 329-339.
|
|
|
|